Therefore, in this study of EZH2 inhibitors involved in MM treatment, we believe that the relationship between EZH2 and CD155 deserves to be taken into account, and attempted to combine treatment with a TIGIT monoclonal antibody, with the aim of achieving a dual inhibition of the TIGIT-CD155 axis. The gene discussed is PVR; the disease is Miyoshi myopathy.